SecBot SecBot
8-K ·Filed Jul 22, 2026

NRXP

NRX Pharmaceuticals, Inc.
BULLISH
Impact 6/10
Horizonweeks Processed3mo ago SEC0001437749-26-024037
8-K context-dependent: Items 8.01
Actionable Insight ▲ Bullish

Monitor for definitive contract award from DARPA, which would provide non-dilutive funding and government validation. The stock may see continued momentum on this government endorsement, but the lack of a binding award means the catalyst is incomplete, watch for follow-up 8-K on contract terms.

DirectionBullish
Confidencemedium
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$4.48
T+0 close · Jul 22, 2026 · via day close
Latest settled
−39.51%
T+60 · $2.71
Vs SPY
−42.77%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 22 $4.48entry
  2. T+1 · 4mo ago −8.26%α −7.02% · $4.11
  3. T+5 · 4mo ago −27.90%α −25.50% · $3.23
  4. T+20 · 3mo ago −25.67%α −28.57% · $3.33
  5. T+60 · 5w ago −39.51%α −42.77% · $2.71
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

NRX Pharmaceuticals' subsidiary NRX Defense Systems received a letter from DARPA indicating its SPARC-TMS clinical trial proposal was selected for negotiation of a potential award. The Phase 2/3 trial combines robotic-enabled TMS with NRX-101 (which has FDA Breakthrough Therapy Designation) for depression remission. This is a non-binding selection, no award has been made and definitive terms remain subject to negotiation, but it represents a significant validation of the company's technology platform by a major government agency.

Key Facts

  • NRX Defense Systems (NRXD) received a letter from DARPA selecting its SPARC-TMS proposal for negotiation of a potential award.
  • The SPARC-TMS trial is a Phase 2/3 trial combining robotic-enabled Transcranial Magnetic Stimulation with NRX-101 (D-cycloserine/lurasidone) for depression remission.
  • NRX-101 previously received FDA Breakthrough Therapy Designation.
  • The trial protocol is FDA-approved and posted on clinicaltrials.gov (NCT07227103).
  • The study is planned at Harvard McLean Hospital, HOPE Therapeutics clinics, and military treatment facilities including Walter Reed.
  • The selection does not constitute a notice of award or commitment by DARPA; final award is subject to successful negotiation of definitive terms.

Financial Impact

No financial terms disclosed. DARPA contract value is TBD and subject to negotiation.

Risk Factors

  • No binding award yet, DARPA may not finalize terms or may cancel negotiations.
  • NRX Pharmaceuticals is a small-cap biotech with no disclosed revenue from this program; the stock may be volatile on binary government contract news.
  • The Phase 2/3 trial carries clinical risk, efficacy or safety issues could derail the program.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
91% bullish (11 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001437749-26-024037
Document: 0001437749-26-024037-index-headers.html0001437749-26-024037
Document: 0001437749-26-024037-index.html0001437749-26-024037
Document: 0001437749-26-024037.txt0001437749-26-024037

Track record

22 reports on NRXP

Performance horizon

8 of 12 bullish or bearish reports moved the stock their way by T+5. Best: +70.33% at T+60 after the Mar 30, 2026 report. 10 of 12 went positive at some point.

Filters
  1. Nov 5, 202611d ago DEFA14A Neutral 3/10 Entry $2.38 to $2.19 Now $2.15 −9.66% ▼ −7.98% −10.58% vs SPY
  2. Nov 5, 202611d ago DEF 14A Neutral 4/10 Entry $2.38 to $2.19 Now $2.15 −9.66% ▼ −7.98% −10.58% vs SPY
  3. Nov 2, 202614d ago 8-K Bullish 6/10 Entry $2.17 to $2.38 Now $2.15 −0.92% ▲ +9.68% +9.60% vs SPY
  4. Oct 30, 202617d ago Press Release Bullish 7/10 Entry $2.27 to $2.38 Now $2.15 −5.29% ▲ +4.85% +7.55% vs SPY
  5. Oct 16, 20264w ago 8-K Neutral 2/10 Entry $2.63 to $2.52 Now $2.15 −18.25% ▼ −4.18% −4.04% vs SPY
  6. Oct 5, 20266w ago 8-K Bullish 6/10 Entry $2.94 to $2.70 Now $2.15 −26.87% ▼ −8.16% −8.02% vs SPY
  7. Sep 15, 20268w ago 8-K Bullish 5/10 Entry $3.35 to $3.16 Now $2.15 −35.82% ▼ −5.67% −8.24% vs SPY
  8. Sep 14, 20269w ago 8-K Neutral 2/10 Entry $3.49 to $3.29 Now $2.15 −38.40% ▼ −5.73% −5.84% vs SPY
  9. Aug 17, 202613w ago 8-K Bullish 7/10 Entry $3.43 to $3.45 Now $2.15 −37.32% ▲ +0.58% +1.77% vs SPY
  10. Aug 17, 202613w ago Press Release Neutral 1/10 Entry $3.43 Now $2.15 −37.32% No price data
Showing 10 of 22

US Market Status

Market Closed · Opens in 6h 21m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 22, 2026